A retrospective cohort study examined cardiometabolic late effects in pediatric acute lymphoblastic leukemia (ALL) survivors. The research utilized linked data from the Arkansas Central Cancer Registry and Arkansas All-Payer Claims Database to compare survivors with cancer-free peers five years after diagnosis. ALL survivors were matched with 426 cancer-free peers based on sex, race, ethnicity, birth year, Medicaid enrollment history, and county of residence.
Key Clinical Findings
The study identified 142 ALL survivors (aged 4-30 years) and matched them with 426 cancer-free peers. Cardiometabolic outcomes were assessed using claims-based diagnoses. Results indicated a significantly higher prevalence of cardiometabolic conditions among ALL survivors compared to matched controls. Specifically, ALL survivors experienced a 10.6% prevalence of cardiometabolic conditions, compared to 1.2% in the matched controls (p < 0.01). The survivors demonstrated a higher prevalence of hypertension (4.9% vs. 0.9%; p < 0.01) and diabetes mellitus (4.9% vs. 0.2%; p < 0.01).
Age-Related Differences
These differences were more pronounced among survivors aged 14 years and older, with 20.4% experiencing at least one cardiometabolic condition compared to 2.0% in the control group (p < 0.01). The study highlights an elevated cardiometabolic risk in pediatric ALL survivors as early as five years after diagnosis, particularly during adolescence. Early screening and preventive strategies are needed to reduce the long-term cardiometabolic burden associated with this population.